Replimune Group, Inc. (NASDAQ:REPL) Receives $17.29 Average PT from Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been given an average recommendation of "Buy" by the eight brokerages that are currently covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $17.29.

A number of equities research analysts recently issued reports on the stock. HC Wainwright reiterated a "buy" rating and set a $17.00 target price on shares of Replimune Group in a research report on Friday, November 22nd. JPMorgan Chase & Co. lifted their target price on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, September 24th. Roth Capital upgraded Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. Jefferies Financial Group lifted their price objective on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, Roth Mkm initiated coverage on Replimune Group in a research note on Tuesday, August 27th. They issued a "buy" rating and a $17.00 price objective on the stock.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 8.80% of the company's stock.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. LMR Partners LLP grew its holdings in Replimune Group by 145.8% during the third quarter. LMR Partners LLP now owns 82,479 shares of the company's stock valued at $904,000 after purchasing an additional 48,920 shares during the period. Millennium Management LLC grew its holdings in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock valued at $650,000 after buying an additional 53,313 shares in the last quarter. Acadian Asset Management LLC raised its stake in Replimune Group by 63.2% during the 2nd quarter. Acadian Asset Management LLC now owns 185,516 shares of the company's stock worth $1,668,000 after buying an additional 71,867 shares during the period. Finally, SG Americas Securities LLC bought a new position in Replimune Group during the third quarter worth about $251,000. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Trading Up 0.2 %

Replimune Group stock traded up $0.03 during midday trading on Friday, reaching $13.08. The stock had a trading volume of 501,174 shares, compared to its average volume of 1,121,904. Replimune Group has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11. The firm's fifty day simple moving average is $12.10 and its two-hundred day simple moving average is $10.24. The firm has a market cap of $894.93 million, a price-to-earnings ratio of -4.29 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.07. Equities analysts anticipate that Replimune Group will post -2.99 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.